United States pharmaceutical maker, Pfizer, and biopharmaceutical company, Global Blood Therapeutics (GBT), on Monday, agreed that Pfizer would acquire GBT in an all-cash deal valued at 5.4 billion U.S. dollars.
Pfizer said the acquisition would drive growth by enhancing its work in rare hematology while reinforcing the company’s commitment to sickle cell disease research and treatment.
According to dpa, under the terms of the transaction, Pfizer will acquire all the outstanding shares of California-based GBT for 68.50 dollars per share in cash, for a total enterprise value of approximately 5.4 billion dollars, including debt and net of cash acquired.
READ ALSO: BioNTech, Pfizer to develop vaccine against shingles
The pharmaceutical company expects to finance the transaction with existing cash on hand.
The proposed transaction, unanimously approved by the Boards of Directors of both companies, is subject to customary closing conditions, including receipt of regulatory approvals and approval by GBT’s stockholders.
The Federal High Court sitting in Lagos State has convicted a surgeon, Dr Anuoluwapo Adepoju,…
Gunmen have abducted one Alhaja Seliat Raji and killed the security guard at her residence…
Barcelona have concluded plans to sack manager Xavi Hernandez just weeks after he made a…
Former Ogun State Governor Olusegun Osoba will chair the opening ceremony of the forthcoming Lagos/Ogun…
The Kano State Police Command has confirmed 15 persons dead in the mosque attack in…
The operatives of the Nasarawa State Police Command have arrested a 400-level student of Nasarawa…
This website uses cookies.